BIOSYENT INC. ("RX")
BULLETIN TYPE: Normal Course Issuer Bid
BULLETIN DATE: December 12, 2019
TSX Venture Tier 2 Company
TSX Venture Exchange has been advised by the Company that pursuant to a Notice of Intention to make a Normal Course Issuer Bid dated December 10, 2019, it may repurchase for cancellation, up to 800,000 shares in its own capital stock. The purchases are to be made through the facilities of TSX Venture Exchange or other recognized marketplaces during the period December 17, 2019 to December 16o, 2020. Purchases pursuant to the bid will be made by Raymond James Ltd. (Matt Malowney) on behalf of the Company.
________________________________________
|
|
